Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Recurrence 5Neoplasm Metastasis 4Lymphoma, T-Cell, Peripheral 4Lymphoma, T-Cell 3Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell 2Lymphoma 2Lung Neoplasms 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Thyroid Diseases 1Smoking 1Polycystic Ovary Syndrome 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Papillomavirus Infections 1Papilloma 1Ovarian Neoplasms 1Neoplasms 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Leukemia 1Laryngeal Diseases 1Infertility 1Immunoblastic Lymphadenopathy 1

Interventions

Vitamin B 12 1Folic Acid 1Erlotinib Hydrochloride 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Smoking × Folic Acid × Clear all
NCT00606502 2021-03-05

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

Spectrum Pharmaceuticals, Inc

Phase 2 Completed
201 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Smoking

Data powered by HemOnc (CC BY 4.0) Colophon âš¡